ArriVent BioPharma (AVBP) Enterprise Value (2023 - 2026)
ArriVent BioPharma (AVBP) posted Enterprise Value of -$326.4 million for Q1 2026, down 4.33% sequentially from -$312.8 million in Q4 2025, and down 85.36% YoY from -$2.2 billion in Q1 2025.
ArriVent BioPharma (AVBP) Enterprise Value (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Enterprise Value for 4 years, with the latest figure at -$326.4 million in Q1 2026.
- Quarterly Enterprise Value fell 85.36% year-over-year to -$326.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$326.4 million (down 85.36% YoY) and the FY2025 annual result came in at -$312.8 million, down 42.93% from the prior year.
- Enterprise Value slipped to -$326.4 million in Q1 2026 per AVBP's latest filing, from -$312.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$124.3 million in Q4 2023 and troughed at -$493.0 million in Q3 2025.
- A 4-year average of -$278.6 million and a median of -$290.8 million in 2024 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2025 and 2026: Enterprise Value jumped 44.52% in 2025, then plunged 85.36% in 2026.
- Over 4 years, Enterprise Value stood at -$124.3 million in 2023, then plunged by 76.08% to -$218.9 million in 2024, then sank by 42.93% to -$312.8 million in 2025, then decreased by 4.33% to -$326.4 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$326.4 million, -$312.8 million, and -$493.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | -591.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -591.54 Mn |
| Mar 31, 2026 | -326.38 Mn |
| Dec 31, 2025 | -312.82 Mn |
| Sep 30, 2025 | -492.99 Mn |
| Jun 30, 2025 | -235.69 Mn |
| Mar 31, 2025 | -176.08 Mn |
| Dec 31, 2024 | -218.86 Mn |
| Sep 30, 2024 | -282.86 Mn |
| Jun 30, 2024 | -298.67 Mn |
| Mar 31, 2024 | -317.39 Mn |
| Dec 31, 2023 | -124.30 Mn |